Hartmann A - Search Results

1

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smi… See abstract for full author list ➔ Horwich A, et al. Among authors: hartmann a. Ann Oncol. 2019 Nov 1;30(11):1697-1727. doi: 10.1093/annonc/mdz296. Ann Oncol. 2019. PMID: 31740927 Free PMC article.

2

High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.

Wild PJ, Kunz-Schughart LA, Stoehr R, Burger M, Blaszyk H, Simon R, Gasser T, Mihatsch M, Sauter G, Hartmann A. Wild PJ, et al. Among authors: hartmann a. Int J Oncol. 2005 Aug;27(2):385-91. Int J Oncol. 2005. PMID: 16010419

3

Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.

Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, Hartmann A, Stoehr R. Denzinger S, et al. Among authors: hartmann a. Hum Pathol. 2006 Feb;37(2):143-51. doi: 10.1016/j.humpath.2005.10.014. Epub 2005 Dec 15. Hum Pathol. 2006. PMID: 16426913

4

Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer.

Burger M, Burger SJ, Denzinger S, Wild PJ, Wieland WF, Blaszyk H, Obermann EC, Stoehr R, Hartmann A. Burger M, et al. Among authors: hartmann a. Eur Urol. 2006 Oct;50(4):770-5; discussion 776. doi: 10.1016/j.eururo.2006.04.010. Epub 2006 May 2. Eur Urol. 2006. PMID: 16762487

5

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.

van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A. van Oers JM, et al. Among authors: hartmann a. Eur Urol. 2007 Sep;52(3):760-8. doi: 10.1016/j.eururo.2007.01.009. Epub 2007 Jan 12. Eur Urol. 2007. PMID: 17240035

6

Spontaneous rupture of a benign giant adrenal adenoma.

Denzinger S, Burger M, Hartmann A, Hofstaedter F, Wieland WF, Ganzer R. Denzinger S, et al. Among authors: hartmann a. APMIS. 2007 Apr;115(4):381-4. doi: 10.1111/j.1600-0463.2007.apm_605.x. APMIS. 2007. PMID: 17504308

7

[Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract].

Burger M, Catto J, van Oers J, Zwarthoff E, Hamdy FC, Meuth M, Azzouri AR, Cussenot O, Wild PJ, Stoehr R, Hartmann A. Burger M, et al. Among authors: hartmann a. Verh Dtsch Ges Pathol. 2006;90:244-52. Verh Dtsch Ges Pathol. 2006. PMID: 17867603 German.

8

Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.

Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, Zwarthoff EC. Burger M, et al. Among authors: hartmann a. Eur Urol. 2008 Oct;54(4):835-43. doi: 10.1016/j.eururo.2007.12.026. Epub 2007 Dec 26. Eur Urol. 2008. PMID: 18166262

9

Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset?

Burger M, Denzinger S, Wieland WF, Stief CG, Hartmann A, Zaak D. Burger M, et al. Among authors: hartmann a. BJU Int. 2008 Jul;102(2):194-7. doi: 10.1111/j.1464-410X.2008.07538.x. Epub 2008 Jul 1. BJU Int. 2008. PMID: 18435811

10

Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics.

Stoehr R, Hitzenbichler F, Kneitz B, Hammerschmied CG, Burger M, Tannapfel A, Hartmann A. Stoehr R, et al. Among authors: hartmann a. Br J Cancer. 2008 Jul 8;99(1):78-82. doi: 10.1038/sj.bjc.6604441. Epub 2008 Jun 24. Br J Cancer. 2008. PMID: 18577987 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,473 results

Search Page

Filters